346 related articles for article (PubMed ID: 33361013)
1. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N
Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013
[TBL] [Abstract][Full Text] [Related]
2. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
3. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B; Li M; Zhou Z; Guan X; Xiang Y
J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
[TBL] [Abstract][Full Text] [Related]
4. Blocking TNF signaling may save lives in COVID-19 infection.
Ablamunits V; Lepsy C
Mol Biol Rep; 2022 Mar; 49(3):2303-2309. PubMed ID: 35076845
[TBL] [Abstract][Full Text] [Related]
5. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
[TBL] [Abstract][Full Text] [Related]
6. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.
Wang J; Yang X; Li Y; Huang JA; Jiang J; Su N
Virol J; 2021 Jun; 18(1):117. PubMed ID: 34088317
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2.
Cheon SY; Koo BN
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360684
[TBL] [Abstract][Full Text] [Related]
8. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
9. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.
Udomsinprasert W; Jittikoon J; Sangroongruangsri S; Chaikledkaew U
J Clin Immunol; 2021 Jan; 41(1):11-22. PubMed ID: 33128665
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 infection: an overview on cytokine storm and related interventions.
Montazersaheb S; Hosseiniyan Khatibi SM; Hejazi MS; Tarhriz V; Farjami A; Ghasemian Sorbeni F; Farahzadi R; Ghasemnejad T
Virol J; 2022 May; 19(1):92. PubMed ID: 35619180
[TBL] [Abstract][Full Text] [Related]
11. IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19.
Leija-Martínez JJ; Huang F; Del-Río-Navarro BE; Sanchéz-Muñoz F; Muñoz-Hernández O; Giacoman-Martínez A; Hall-Mondragon MS; Espinosa-Velazquez D
Med Hypotheses; 2020 Nov; 144():109935. PubMed ID: 32795834
[TBL] [Abstract][Full Text] [Related]
12. Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients.
Mortaz E; Tabarsi P; Jamaati H; Dalil Roofchayee N; Dezfuli NK; Hashemian SM; Moniri A; Marjani M; Malekmohammad M; Mansouri D; Varahram M; Folkerts G; Adcock IM
Front Immunol; 2021; 12():592727. PubMed ID: 33968010
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.
Perlin DS; Neil GA; Anderson C; Zafir-Lavie I; Raines S; Ware CF; Wilkins HJ
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34871182
[TBL] [Abstract][Full Text] [Related]
14. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
15. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
17. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.
Amigues I; Pearlman AH; Patel A; Reid P; Robinson PC; Sinha R; Kim AH; Youngstein T; Jayatilleke A; Konig M
Expert Rev Clin Immunol; 2020 Dec; 16(12):1185-1204. PubMed ID: 33146561
[No Abstract] [Full Text] [Related]
19. Fighting the storm: could novel anti-TNFα and anti-IL-6
Kovalchuk A; Wang B; Li D; Rodriguez-Juarez R; Ilnytskyy S; Kovalchuk I; Kovalchuk O
Aging (Albany NY); 2021 Jan; 13(2):1571-1590. PubMed ID: 33465050
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
